Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

NCT02461589 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

706

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: semaglutide
DRUG: liraglutide
DRUG: placebo

Sponsor

Novo Nordisk A/S